Longitudinal Survey Analysis in Lymphoma Survivors (CLEAR Stress)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT01469754
First received: November 8, 2011
Last updated: May 1, 2014
Last verified: May 2014
  Purpose

Posttraumatic Stress Disorder (PTSD) is a well-documented phenomenon that occurs in cancer survivors. PTSD is known to cause problems with anxiety, depression, and quality of life. Furthermore, there is little treatment available for cancer survivors who suffer from PTSD.

Posttraumatic Growth, however, is a lesser known phenomenon that also occurs in cancer survivors. It is a positive psychological phenomenon that occurs in some people who have suffered a traumatic event--the people who are able to note a "greater appreciation for life", a "stronger relationship with their family/friends," or a "new found level of spirituality" are examples of instances of posttraumatic growth.

Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress) is a study designed to compare the development of PTSD versus the development of Posttraumatic Growth in lymphoma patients at any stage of the cancer experience, regardless of treatment. The hypothesis is that posttraumatic growth, if it is significant, can reduce the impact of PTSD symptoms in the survivor.


Condition
Lymphoma
Posttraumatic Stress Disorder
Posttraumatic Growth
Coping
Resilience

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors

Resource links provided by NLM:


Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • Posttraumatic Growth [ Time Frame: Measured at enrollment ]

Secondary Outcome Measures:
  • Posttraumatic Stress Disorder (PTSD) [ Time Frame: Measured at Enrollment ]

Enrollment: 97
Study Start Date: September 2011
Study Completion Date: September 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Lymphoma Survivors

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Lymphoma survivors who have completed initial treatment within the last 3 months

Criteria

Inclusion Criteria:

  • Diagnosis of Lymphoma (includes Waldenstrom's Macroglobulinemia)
  • Can read/write/understand English without a translator

Exclusion Criteria:

  • Currently Hospitalized
  • Active Psychosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01469754

Locations
United States, New York
New York Presbyterian/Weill Cornell Center for Lymphoma and Myeloma
New York, New York, United States, 10065
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Principal Investigator: Regina A Jacob, MD WCMC Research Fellow
  More Information

No publications provided

Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT01469754     History of Changes
Other Study ID Numbers: 1107011786
Study First Received: November 8, 2011
Last Updated: May 1, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Weill Medical College of Cornell University:
lymphoma
survivors
posttraumatic growth
posttraumatic stress
longitudinal

Additional relevant MeSH terms:
Lymphoma
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 28, 2014